Does liposomal doxorubicin-based chemotherapy improve ORR and reduce cardiotoxicity in patients with advanced breast cancer?
Patients with advanced breast cancer (meta-analysis of 10 randomized controlled trials)
Liposomal doxorubicin-based chemotherapy
Objective Response Rate (ORR) and cardiotoxicitysafety
Liposomal doxorubicin-based chemotherapy improves objective response rates and reduces cardiotoxicity in advanced breast cancer.
The results of this meta-analysis suggest that liposomal doxorubicin-based chemotherapy is associated with a significant improvement in the ORR and a significant reduction in the risk of cardiotoxicity.
Building similarity graph...
Analyzing shared references across papers
Loading...
Mei‐Yuan Xing
Feifei Yan
Sufen Yu
SHILAP Revista de lepidopterología
PLoS ONE
Zhejiang University
Building similarity graph...
Analyzing shared references across papers
Loading...
Xing et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69d56e1c75589c71d767d3c8 — DOI: https://doi.org/10.1371/journal.pone.0133569